Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
Trevi Therapeutics announced that CEO Jennifer Good and CFO David Hastings will participate in a fireside chat at the Stifel 2026 Healthcare Conference on November 11 at 10:00 a.m. ET, alongside investor meetings. The company's lead asset is Haduvio (oral nalbuphine ER), in development for chronic cough in IPF, non-IPF ILD, and refractory chronic cough, with prior trials showing statistically significant cough-frequency reductions.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.